The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC).
 
Kevin Jao
No Relationships to Disclose
 
Pascale Tomasini
No Relationships to Disclose
 
Suzanne Kamel-Reid
No Relationships to Disclose
 
Ming Sound Tsao
Honoraria - AstraZeneca; Novartis; Pfizer; Precision Therapeutics; Roche/Genentech
Speakers' Bureau - Boehringer Ingelheim; Pfizer
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Prognostic gene signature for early stage non-small cell lung cancer
 
Gregorz J Korpanty
No Relationships to Disclose
 
Celine Mascaux
No Relationships to Disclose
 
Geoffrey Liu
Honoraria - novartis; pfizer
Consulting or Advisory Role - novartis; pfizer
Research Funding - roche (Inst)
 
Natasha B. Leighl
Research Funding - Roche Canada (Inst)
 
Ronald Feld
No Relationships to Disclose
 
Penelope Ann Bradbury
No Relationships to Disclose
 
Marguerite Ennis
No Relationships to Disclose
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Merck/Schering Plough; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Lilly
Research Funding - Boehringer Ingelheim (Inst)
Travel, Accommodations, Expenses - Novartis